Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 256 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fish oil placebo Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

NCT04796207
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions
Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 17, 2026, 1:47 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

n-3 PUFA for Vascular Cognitive Aging

NCT01953705
View directory record Official record
Conditions
Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
Interventions
Omega 3 PUFA, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
75 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 17, 2026, 1:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Lutein, Zeaxathin, and Fish Oil Supplementation

NCT06489873
View directory record Official record
Conditions
Cognitive Performance, Age-Related Macular Degeneration, Bone Loss
Interventions
Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF), Placebo Comparator
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

NCT02094534
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
ORMD-0801 Capsules, Placebo
Biological · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Minimum Time Effect of Fish Oil on Arterial Stiffness

NCT06981364
View directory record Official record
Conditions
Arterial Stiffness
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
Salisbury University
Other
Eligibility
18 Years to 30 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline

NCT01669915
View directory record Official record
Conditions
Cognitive Decline
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 92 Years
Enrollment
3,424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 1 Interventional

Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream

NCT00690625
View directory record Official record
Conditions
Myofacial Pain
Interventions
MyoRx Cream (6% Omega 3 Fatty Acid), Placebo cream, no Omega 3 fatty acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2008 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Results available

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

NCT01563913
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Docosahexaenoic Acid (DHA), Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 2Phase 3 Interventional

The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease

NCT02260960
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Omega-3 (Triglyceride form)
Dietary Supplement
Lead sponsor
Physician Recommended Nutriceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus

NCT04564846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention

NCT01780974
View directory record Official record
Conditions
Treated Hypertension
Interventions
Lipoic Acid plus Omega-3 Fatty Acids, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 17, 2026, 1:47 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

LungVITamin D and OmegA-3 Trial (lungVITAL)

NCT01728571
View directory record Official record
Conditions
COPD, Asthma, Pulmonary Function, Pneumonia
Interventions
Vitamin D3, fish oil, Vitamin D3 placebo, Fish oil placebo
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 17, 2026, 1:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

NCT03784963
View directory record Official record
Conditions
Heart Failure, Gastrointestinal Bleeding
Interventions
Omega 3 fatty acids, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 17, 2026, 1:47 AM EDT
Terminated Phase 4 Interventional Results available

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

NCT00592683
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
Aripiprazole, fish oil, Placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 2Phase 3 Interventional

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

NCT00585390
View directory record Official record
Conditions
Schizophrenia, Fatty Acid Deficiency
Interventions
Omega-3 Fatty Acids, Olive oil placebo, EPA fish oil concentrate; DHA fish oil concentrate, Placebo
Dietary Supplement · Other · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Sep 17, 2026, 1:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers

NCT05121766
View directory record Official record
Conditions
COVID-19
Interventions
Omega-3 (EPA+DHA), Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 1:47 AM EDT
Terminated Phase 2 Interventional Results available

Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

NCT02940223
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Fatigue
Interventions
Ethyl Icosapentate, Exercise Intervention, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation

NCT00552084
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Fish oil, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Results available

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

NCT01733147
View directory record Official record
Conditions
Barrett's Esophagus, Obesity
Interventions
Omega-3 polyunsaturated fatty acids, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

NCT00835289
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
n-3 polyunsaturated fatty acids, Placebo
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

DHA and X-Linked Retinitis Pigmentosa

NCT00100230
View directory record Official record
Conditions
Retinitis Pigmentosa, X-linked Genetic Diseases
Interventions
docosahexaenoic acid OR corn/soy oil placebo
Drug
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
7 Years to 32 Years · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Actions of Omega-3 Fatty Acids

NCT01896414
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA (marine fatty acids), Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 17, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 17, 2026, 1:47 AM EDT